Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy.
S
S
Shibata
Y
Y
Tada
C
C
Hau
A
A
Tatsuta
M
M
Yamamoto
M
M
Kamata
M
M
Karakawa
Y
Y
Asano
H
H
Mitsui
M
M
Sugaya
T
T
Kadono
H
H
Saeki
N
N
Kanda
S
S
Sato
D000068879:Adalimumab; D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000097:blood / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy; D012720:Severity of Illness Index; D014467:Ultraviolet Therapy / Q000379:methods
D052242:Adiponectin; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D000069285:Infliximab; D000068879:Adalimumab